Article
Brochure
Insight Hub
Executive Resource
Ext. Publication
Video
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.
With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
Weaver’s transaction advisory team guides clients through the deal lifecycle with M&A strategies and due diligence efforts to keep clients informed, proactive and confident.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.
The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.
Featured in American Health Law Association’s online publication, Weaver partners Corey Palasota and Tashiana Briggs outline personal goodwill in health care M&A transactions.
The home health and hospice sectors are facing significant challenges with personal care emerging as the key sector for mitigating risk.